{
  "abstract": "To date, no randomized controlled trial has compared different dose-schedule patterns of raltitrexed combined with irinotecan for the second-line treatment of metastatic colorectal cancer (mCRC). This study aimed to evaluate the efficacy and safety of raltitrexed combined with irinotecan administered by different dose-schedule patterns as a second-line treatment for mCRC. This was an exploratory, observational post hoc analysis of data from the SALLY study, a prospective, multicenter, noninterventional, real-world trial conducted in China. The core eligibility criteria of the SALLY study were mCRC that had failed to respond to first-line treatments comprising 5-fluorouracil (5-FU) + platinum-based chemotherapy. The regimen was administered every 2 or 3 weeks at the corresponding dose. The treatment frequency was determined by the attending physician. Among the 1,066 enrolled patients in the SALLY study, 618 (58.0%) received treatment every 3 weeks and 441 (41.3%) received treatment every 2 weeks in the full analysis set (FAS). There were no statistically significant differences in progression-free survival (PFS), overall survival (OS), objective response rate (ORR), or disease control rate (DCR) between the two groups in the FAS or in the per-protocol set (PPS). In the every-2-week group, 75.1% of patients experienced treatment-related adverse effects (AEs), compared with 77.5% of patients in the every-3-week group (P=0.38). The incidences of grade 3 or 4 toxicities were 10.9% (48/441) and 14.4% (89/619), respectively (P=0.11). In the second-line treatment of mCRC, the efficacy of irinotecan plus raltitrexed administered every 2 weeks with its corresponding dose did not differ significantly from that administered every 3 weeks.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.",
    "Department of Oncology, Second Hospital of Jiaxing, Jiaxing, China.",
    "Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.",
    "Department of Oncology, Shaoxing People's Hospital, Shaoxing, China.",
    "Zhejiang Provincial Clinical Research Center for CANCER, Hangzhou, China.",
    "Cancer Center of Zhejiang University, Hangzhou, China.",
    "Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, Hangzhou, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Nuoya Yu"
    },
    {
      "affs": [
        0
      ],
      "name": "Ziyan Tong"
    },
    {
      "affs": [
        1
      ],
      "name": "Yaohua Fan"
    },
    {
      "affs": [
        2
      ],
      "name": "Zishu Wang"
    },
    {
      "affs": [
        3
      ],
      "name": "Jianfang Wang"
    },
    {
      "affs": [
        0,
        4,
        5,
        6
      ],
      "name": "Ying Yuan"
    },
    {
      "affs": [
        0
      ],
      "name": "Shanshan Weng"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/a9yb60nz67cvf.bib",
  "cited_by": 0,
  "doi": "10.21037/jgo-2026-1127",
  "fulltext_url": "https://europepmc.org/articles/PMC13740559",
  "id": "a9yb60nz67cvf",
  "issns": [
    "2078-6891",
    "2219-679X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42996882",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Colorectal Cancer Treatments and Studies"
    ]
  ],
  "openalex": "W7224079123",
  "pdf_url": "https://europepmc.org/articles/PMC13740559?pdf=render",
  "pmcid": "PMC13740559",
  "pmid": "42996882",
  "published": "2026-10-27",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/a9yb60nz67cvf.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:34Z",
      "native_id": "MED:42996882",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42996882"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Colorectal Cancer Treatments and Studies",
      "subfield": "oncology"
    }
  ],
  "title": "Comparing the efficacy and safety of raltitrexed combined with irinotecan administered in different dose-schedule patterns for the second-line treatment of metastatic colorectal cancer: an exploratory, observational post hoc analysis from the prospective SALLY registry cohort.",
  "title_text": "Comparing the efficacy and safety of raltitrexed combined with irinotecan administered in different dose-schedule patterns for the second-line treatment of metastatic colorectal cancer: an exploratory, observational post hoc analysis from the prospective SALLY registry cohort.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:34Z",
  "url": "https://research.draconitic.com/paper/a9yb60nz67cvf",
  "venue": "Journal of gastrointestinal oncology",
  "versions": []
}